10-Q: Onconetix Reports Q3 2024 Results, Faces Going Concern Uncertainty Amidst Strategic Shift

Sentiment:

Quarterly Report 9 December 2024 8:16 PM

Onconetix's Q3 2024 report reveals a net loss of $3.8 million and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Delay expectedThe company has paused its commercialization of ENTADFI during the first quarter of 2024, as it explores strategic alternatives to monetize the asset.

Capital raiseThe company will require significant additional capital in the short-term to fund its continuing operations, satisfy existing and future obligations and liabilities, and support its working capital needs and business activities.Management intends to secure additional required funding through equity or debt financings if available, and to utilize the ELOC entered into in October 2024 on an as-needed basis.There is no assurance that such financing will be available to the Company on favorable terms, if at all.

Worse than expectedThe company's financial results were worse than expected due to significant net losses, a low cash balance, a substantial working capital deficit, and an accumulated deficit.The company's ability to continue as a going concern is in doubt, which is a significant negative indicator.The company's decision to pause commercialization of ENTADFI and explore strategic alternatives indicates a lack of confidence in the product's market potential.

Summary

Onconetix, a commercial-stage biotechnology company, reported a net loss of $3.8 million for the third quarter of 2024, and a net loss of $29.3 million for the nine months ended September 30, 2024.
The company's cash balance was approximately $0.3 million as of September 30, 2024, and $0.4 million as of December 5, 2024, with all cash held by its foreign subsidiary.
Onconetix has a working capital deficit of approximately $16.3 million and an accumulated deficit of approximately $86.0 million as of September 30, 2024.
The company used approximately $9.6 million in cash for operating activities during the nine months ended September 30, 2024.
There is substantial doubt about Onconetix's ability to continue as a going concern within one year from the issuance of these financial statements.
The company is exploring strategic alternatives for its ENTADFI asset, including a potential sale, and has paused its commercialization efforts for this product.
Onconetix is focusing on the commercialization of Proclarix, a prostate cancer diagnostic test, and expects to generate revenue from sales by 2026.
The company has entered into a licensing agreement with LabCorp for the commercialization of Proclarix in the United States.
Onconetix completed a reverse stock split at a ratio of 1:40 on September 24, 2024.
The company has a significant amount of debt, including $9.8 million due within the next 12 months.

Sentiment

Score: 2

Explanation: The document presents a highly negative outlook due to significant financial losses, a going concern warning, and the need for substantial additional capital. The strategic shift away from ENTADFI and reliance on a single product, Proclarix, further contribute to the negative sentiment.

Positives

Onconetix is focusing on the commercialization of Proclarix, a prostate cancer diagnostic test, which has CE mark approval in the European Union.
The company has a licensing agreement with LabCorp for the commercialization of Proclarix in the United States.
Onconetix generated approximately $1.8 million in revenue during the nine months ended September 30, 2024, primarily from development services and product sales related to Proclarix.
The company has taken steps to reduce operating expenses by pausing commercialization of ENTADFI and terminating related employees.

Negatives

Onconetix has incurred significant net losses since inception and expects to continue to incur substantial net losses for the foreseeable future.
The company has a significant working capital deficit and an accumulated deficit.
There is substantial doubt about Onconetix's ability to continue as a going concern.
The company has paused commercialization of ENTADFI and is exploring strategic alternatives, including a potential sale, and may abandon the assets.
Onconetix is dependent on third parties, including LabCorp, for the development, marketing, distribution, and sale of its products.
The company has a significant amount of debt, including $9.8 million due within the next 12 months.
The company recorded significant impairment losses on goodwill and ENTADFI assets.
The company's disclosure controls and procedures were not effective as of September 30, 2024, due to material weaknesses in internal control over financial reporting.

Risks

Onconetix faces significant financial risks, including the need for substantial additional capital to fund operations and repay debts.
The company's ability to commercialize Proclarix and generate revenue is uncertain.
Onconetix is dependent on third parties, including LabCorp, for the development, marketing, distribution, and sale of its products, and any failure by these partners could adversely affect the company.
The company's strategic alternatives for ENTADFI, including a potential sale, may not be successful, and the company may abandon the assets.
The company's material weaknesses in internal control over financial reporting could lead to misstatements in financial statements.
The company's stock price has declined significantly, which could trigger further impairment tests.

Future Outlook

Onconetix expects to continue to incur substantial operating losses for the foreseeable future and will require significant additional capital to fund its operations. The company anticipates generating revenue from sales of Proclarix by 2026, but there is no guarantee of success. The company is also exploring strategic alternatives for its ENTADFI asset, including a potential sale.

Management Comments

Management's plans for funding the Company's operations include generating product revenue from sales of Proclarix.
Management also intends to secure additional required funding through equity or debt financings if available, and to utilize the ELOC entered into in October 2024 on an as-needed basis.
Management determined that the funds readily available under the ELOC will not be sufficient to sustain operations.

Industry Context

The announcement reflects the challenges faced by early-stage biotechnology companies in commercializing products and securing funding. The company's strategic shift towards Proclarix and away from ENTADFI highlights the need for adaptability in the face of market and financial pressures. The reliance on third-party partners like LabCorp is common in the industry, but also introduces risks related to partner performance and control.

Comparison to Industry Standards

The company's cash burn rate of $9.6 million for the nine months ended September 30, 2024, is significant for a company of its size and stage, and is higher than many comparable companies in the biotech sector.
The company's reliance on a single product, Proclarix, for future revenue generation is a high-risk strategy, as many biotech companies have a diversified pipeline of products.
The company's debt burden of $9.8 million due within the next 12 months is substantial and could limit its ability to invest in growth and development.
The company's decision to pause commercialization of ENTADFI and explore strategic alternatives is a common strategy for companies facing financial difficulties, but it also indicates a lack of confidence in the product's market potential.
The company's material weaknesses in internal control over financial reporting are a serious concern and are not typical for publicly traded companies, indicating a need for significant improvements in its financial management and governance.

Legal Proceedings

WraSer has advised the Company that it does not believe that a Material Adverse Effect occurred, and they recently filed a plan of reorganization that indicates it may seek damages from the Company due to the termination of the WraSer APA and WraSer MSA.

Related Party Transactions

The company issued a non-convertible debenture in the principal amount of $5.0 million to the PMX Investor, a related party, in connection with the Subscription Agreement.
The company converted all unpaid principal and accrued interest due under the Debenture into 500,000 units, attributable to principal, and 13,424 units, attributable to accrued interest, upon the closing of the Subscription Agreement.

Stakeholder Impact

Shareholders face significant risks due to the company's financial instability and the potential for further dilution.
Employees may be affected by potential cost-cutting measures and the uncertainty surrounding the company's future.
Customers and partners may be concerned about the company's ability to deliver on its commitments.
Creditors face the risk of non-payment and potential losses.

Next Steps

The company will continue to explore strategic alternatives for ENTADFI, including a potential sale.
Onconetix will focus on the commercialization of Proclarix and expects to generate revenue from sales by 2026.
The company will seek additional funding through equity or debt financings and utilize the ELOC as needed.
Onconetix will implement a remediation plan to address material weaknesses in internal control over financial reporting.

Key Dates

Date	Description
2018-10-26	Onconetix, Inc. was formed.
2023-03-23	Proteomedix entered into a license agreement with LabCorp.
2023-04-19	Onconetix entered into an Asset Purchase Agreement with Veru, Inc. to acquire ENTADFI.
2023-07-21	Onconetix entered into a Licensing and Services Master Agreement with IQVIA.
2023-09-24	Onconetix filed a Certificate of Designations of Rights and Preferences of Series A Preferred Stock.
2023-09-29	Onconetix entered into an amendment to the Veru APA.
2023-10-03	Onconetix issued 3,000 shares of Series A Convertible Preferred Stock to Veru.
2023-12-15	Onconetix acquired Proteomedix AG.
2023-12-18	Onconetix entered into a subscription agreement with the PMX Investor.
2024-01-23	Onconetix issued a non-convertible debenture to the PMX Investor.
2024-04-24	Onconetix entered into a forbearance agreement with Veru.
2024-07-11	Onconetix entered into common stock preferred investment options exercise inducement offer letters.
2024-09-05	Stockholder approval was obtained for certain transactions involving the company's Series B Preferred Stock.
2024-09-19	Onconetix entered into an Amended and Restated Forbearance Agreement with Veru.
2024-09-24	Onconetix effected a reverse stock split of 1:40, converted Series A and B Preferred Stock to common stock, and issued units to the PMX Investor.
2024-10-01	The Board of Directors authorized the Company to create a series of 10,000 shares of preferred stock designated as Series C Convertible Preferred Stock.
2024-10-02	Onconetix entered into a Common Stock ELOC Purchase Agreement and sold Series C convertible preferred stock and warrants to institutional investors.
2024-11-13	The Board terminated the stock repurchase program.
2024-11-26	Onconetix entered into another Amended and Restated Forbearance Agreement with Veru.
2024-12-05	The company's cash balance was approximately $0.4 million.

Keywords

Onconetix, Proclarix, ENTADFI, biotechnology, prostate cancer, diagnostics, commercialization, financial results, going concern, debt, impairment, LabCorp, reverse stock split

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.